BIOMAT Database Logo BIOMAT Database Logo

Intensive chemotherapy of poor prognosis myelodysplastic syndromes (MDS) and acute myeloid leukemia following MDS with idarubicin and cytarabine. 1997

T Ruutu, and A Hänninen, and G Järventie, and P Koistinen, and E Koivunen, and K Kätkä, and T Nousiainen, and K Oksanen, and T T Pelliniemi, and K Remes, and T Timonen, and L Volin, and E Elonen
Helsinki University Central Hospital, Finland.

Forty patients with high risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) preceded by MDS were treated with intensive induction and consolidation chemotherapy in a prospective multicenter pilot study. They were given two cycles of cytarabine 100 mg/m with 12-h intervals on days 1-7 and idarubicin 12 mg/m2 on days 5-7, both intravenously. Patients who were in remission after these two cycles were given two further cycles of cytarabine on days 1-5 and idarubicin on day 5. No maintenance treatment was given. Eleven out of 19 MDS patients (58%) and 10 out of 21 AML patients (48%), in total 21 out of 40 patients (53%), entered remission. Eight patients underwent allogeneic bone marrow transplantation. The follow-up time was 13-48 (median 33) months. At the time of the analysis, seven patients survived, four patients with MDS all of whom had been treated with bone marrow transplantation (three in continuous remission), and three patients with AML treated with chemotherapy only (two in continuous remission). The median survival of the patients treated with chemotherapy only was 12 months, with the median progression-free survival being 8 months. In view of the poor prognostic factors of the patients, the remission rate was satisfactory, but the responses as well as the survival were short. The post-remission treatment needs to be improved.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009190 Myelodysplastic Syndromes Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA. Dysmyelopoietic Syndromes,Hematopoetic Myelodysplasia,Dysmyelopoietic Syndrome,Hematopoetic Myelodysplasias,Myelodysplasia, Hematopoetic,Myelodysplasias, Hematopoetic,Myelodysplastic Syndrome,Syndrome, Dysmyelopoietic,Syndrome, Myelodysplastic,Syndromes, Dysmyelopoietic,Syndromes, Myelodysplastic
D010865 Pilot Projects Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work. Pilot Studies,Pilot Study,Pilot Project,Project, Pilot,Projects, Pilot,Studies, Pilot,Study, Pilot
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

T Ruutu, and A Hänninen, and G Järventie, and P Koistinen, and E Koivunen, and K Kätkä, and T Nousiainen, and K Oksanen, and T T Pelliniemi, and K Remes, and T Timonen, and L Volin, and E Elonen
Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
August 2004, Annals of hematology,
T Ruutu, and A Hänninen, and G Järventie, and P Koistinen, and E Koivunen, and K Kätkä, and T Nousiainen, and K Oksanen, and T T Pelliniemi, and K Remes, and T Timonen, and L Volin, and E Elonen
Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS.
October 2001, Blood,
T Ruutu, and A Hänninen, and G Järventie, and P Koistinen, and E Koivunen, and K Kätkä, and T Nousiainen, and K Oksanen, and T T Pelliniemi, and K Remes, and T Timonen, and L Volin, and E Elonen
Vancomycin-resistant enterococci in acute myeloid leukemia and myelodysplastic syndrome patients undergoing induction chemotherapy with idarubicin and cytarabine.
November 2017, Leukemia & lymphoma,
T Ruutu, and A Hänninen, and G Järventie, and P Koistinen, and E Koivunen, and K Kätkä, and T Nousiainen, and K Oksanen, and T T Pelliniemi, and K Remes, and T Timonen, and L Volin, and E Elonen
[Acute myeloid leukemia with poor prognosis: treatment with oral 4-demethoxydaunorubicin (idarubicin) and low-dose cytarabine via subcutaneous route].
April 1990, Schweizerische medizinische Wochenschrift,
T Ruutu, and A Hänninen, and G Järventie, and P Koistinen, and E Koivunen, and K Kätkä, and T Nousiainen, and K Oksanen, and T T Pelliniemi, and K Remes, and T Timonen, and L Volin, and E Elonen
Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia.
December 1997, British journal of haematology,
T Ruutu, and A Hänninen, and G Järventie, and P Koistinen, and E Koivunen, and K Kätkä, and T Nousiainen, and K Oksanen, and T T Pelliniemi, and K Remes, and T Timonen, and L Volin, and E Elonen
Outpatient management following intensive induction chemotherapy for myelodysplastic syndromes and acute myeloid leukemia: a pilot study.
June 2011, Haematologica,
T Ruutu, and A Hänninen, and G Järventie, and P Koistinen, and E Koivunen, and K Kätkä, and T Nousiainen, and K Oksanen, and T T Pelliniemi, and K Remes, and T Timonen, and L Volin, and E Elonen
Intensive timed chemotherapy for 51 acute myeloid leukemia patients with poor prognosis.
June 1985, Seminars in oncology,
T Ruutu, and A Hänninen, and G Järventie, and P Koistinen, and E Koivunen, and K Kätkä, and T Nousiainen, and K Oksanen, and T T Pelliniemi, and K Remes, and T Timonen, and L Volin, and E Elonen
Induction of Acute Myeloid Leukemia with Idarubicin, Cytarabine and Cladribine.
November 2015, Anticancer research,
T Ruutu, and A Hänninen, and G Järventie, and P Koistinen, and E Koivunen, and K Kätkä, and T Nousiainen, and K Oksanen, and T T Pelliniemi, and K Remes, and T Timonen, and L Volin, and E Elonen
CircZBTB46 predicts poor prognosis and promotes disease progression of myelodysplastic syndromes and acute myeloid leukemia.
December 2023, Clinical and experimental medicine,
T Ruutu, and A Hänninen, and G Järventie, and P Koistinen, and E Koivunen, and K Kätkä, and T Nousiainen, and K Oksanen, and T T Pelliniemi, and K Remes, and T Timonen, and L Volin, and E Elonen
Myelodysplastic syndromes (MDS) and acute myeloid leukemias (AML) with myelofibrosis.
January 1992, Leukemia research,
Copied contents to your clipboard!